DELRAY BEACH, Fla., Jan. 13, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Predictive Clinical Biomarkers Market is projected to grow from about USD 8.49 billion in 2025 to USD 14.69 billion by 2030, at a CAGR of 11.6%.
Browse 708 market data tables and 56 figures spread through 506 pages and an in-depth TOC on "Predictive Clinical Biomarkers Market - Global Forecast to 2030"
Predictive Clinical Biomarkers Market Size & Forecast:
- Market Size Available for Years: 2024-2030
- 2025 Market Size: USD 8.49 billion
- 2030 Projected Market Size: USD 14.69 billion
- CAGR (2025-2030): 11.6%
Predictive Clinical Biomarkers Market Trends & Insights:
- By type, the consumables segment is expected to dominate the market by revenue share.
- By technology, the PCR segment dominate the predictive clinical biomarkers market.
- By application, the cancer segment is expected to dominate the predictive clinical biomarkers market.
- The Asia Pacific predictive clinical biomarkers market was the fastest growing segment with CAGR 13.2% in 2024.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97566514
The predictive clinical biomarkers market is experiencing growth due to several key factors, such as the integration of biomarkers into clinical trial design and the increasing adoption of targeted therapies and immunotherapies.
Emerging technologies, including AI-driven analysis of multiplex biomarker data, highly automated IVD workflows, and increasingly sensitive liquid-biopsy assays, are transforming the predictive clinical biomarkers landscape by making complex stratification tests faster and more practical for routine oncology care. At the same time, regulators' emphasis on companion diagnostics and minimal residual disease-style response monitoring is pushing laboratories toward more standardized, clinically validated predictive biomarker panels that directly inform therapy selection, dose adjustment, and real-time tracking of treatment failure or relapse.
By technology, the immunoassay segment accounted for the largest share of the predictive clinical biomarkers market, by technology.
the immunoassay segment accounted for the largest share of the predictive clinical biomarkers market in 2024. Clinical laboratories, cancer centers, and pharmaceutical companies increasingly favor immunoassay platforms because they enable high-throughput, cost-effective measurement of proteins, cytokines, and other circulating markers, making them ideal for routine disease monitoring and for validating prognostic and predictive biomarkers signatures.
Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=97566514
In 2024, the personalized medicines segment registered the fastest growth.
Personalized medicine is emerging as the fastest-growing use of predictive clinical biomarkers because doctors can match each patient to the most effective therapy upfront, avoid unnecessary side effects, and adjust treatment as the disease evolves, turning lab results into more precise, individualized care pathways.
North america accounted for the largest regional share in the predictive clinical biomarkers market in 2024.
The predictive clinical biomarkers market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America holds the largest share, supported by a dense network of academic centers, cancer institutes, and commercial labs that have widely adopted NGS testing, liquid biopsies, and companion diagnostics. Favorable reimbursement, flagship government initiatives such as the Cancer Moonshot, and strong pharma-biotech investment in biomarker-driven clinical trials further reinforce North America's leading position in genomics biomarkers revenues.
Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=97566514
Top Companies in Predictive Clinical Biomarkers Market:
The Top Companies in Predictive Clinical Biomarkers Market include Thermo Fisher Scientific Inc. (US), F. QIAGEN (Germany), Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Abbott (US), Pacbio (US), Illumina, Inc. (US).
Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting
Related Reports:
Biomarkers Market - Global Forecast to 2030
Next Generation Sequencing Market - Global Forecast to 2029
PCR Technologies Market - Global Forecast to 2030
Cancer Biomarkers Market - Global Forecast to 2029
Digital PCR and qPCR Market - Global Forecast to 2029
About MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo - https://mma.prnewswire.com/media/1868219/5714706/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/predictive-clinical-biomarkers-market-worth-14-69-billion-by-2030--marketsandmarkets-302659576.html
